 Today, I have the pleasure of speaking with André Laurent from Diagnose. How are you today, André? I'm doing very well. You yourself, Tracy? You've been knocking, basically, home runs right out of the ballpark here, week after week, this last month, as you told us you would be. Most recent news, you've entered into an exclusive distribution agreement to access massive global health care market in Dutch countries and central Europe of over 140 million people. That seems like a good start. Why don't you tell us more about this deal? Yeah, we've been trying to get into the Dutch area. So that's Eastern Europe, all the German speaking countries. And the reason why we're trying to get in there is that the German government, for example, is very, very hot about wellness programs and how they can reduce costs, medium and long term. And that's why we're trying to get in there. So we actually have now the right partner with the right contacts. And so we're very pleased. Well, I think more importantly, you've got the infrastructure now. You're in Switzerland, Austria. Am I missing anything else here from the news release? I was really enjoying your news when I saw it cross the wire. Well, we're setting up in those countries. So right now, our partner is setting up in those countries. They've hired the right people. The market is big. It's 100 million people plus. It's a very large market for diabetics and also for people that suffer from hypertension. So for us, it's great. And we did a lot of work in Geneva, for example, Switzerland before, and the welcoming was very good on the technology. Now that we have a local partner, I hope to accelerate the installations and the revenue there. So Andre, many of us are looking at wellness. I was talking to my investment advisor. He thought he had a stroke and was in the hospital all night a couple of weeks ago. And I see here you as well announced a successful proof of concept pilot study. Talk to us about this. This sounds very exciting and use the AI term as often as you can, Andre, because that's another sector everybody's eyeing presently. Oh, absolutely. I saw this one coming from a long time ago. And two weeks ago, the association of strokes in the U.S. came out with a technical, well, the American Stroke Association came out with a study that actually shows the relationship between being diabetic and having a stroke. And mainly about the size of the blood vessels, so the arteries and veins. And what we do when we take the picture of the retina, we see the arteries and veins and we see the impact of that. So they came up with this study and they did the 1200 people. And so it just supports what we've been doing for the last three or four years. And as I promised you very soon, we're going to have a clinical trial in the U.S. very, very soon and also in Canada. The pilot was very successful. It demonstrated what we're looking for. And it's to identify people in the early stage of being at risk of having a stroke. So the reflection of the size of the blood vessels and other little things that happen in your eye actually reflects that. And the conclusion of our pilot was it did the reflection at 99 percent. All right. Well, if that doesn't give you something to look forward to, you're putting out news regularly. I mean, all of these things we're talking about are just in the last four weeks alone. You also made a, you signed with the third largest optical retailer in Costa Rica, piloting Cara. Could you tell us more about this deal? Yeah. So we just finished the installation. And this is the third largest optical store. And they are just trying out the technology. And they're very, very, very happy. They're very pleased with the outcome. We started about a week and a half ago. So the idea there is to start with one store, then two and three and then go all the way up to finish implementing this in all their stores. You're probably going to take the next 12 to 18 months. But it's going to increase our revenues monthly. And it's a very, very practical model over there. It really, really helps patients to make sure they don't, you know, either lose their vision or even go into very expensive medication. Because in Costa Rica, the cost of living is still significant when you're sick. So what should investors out there, you know, why should they be looking at diagnosis now? I'm going to put you right on the spot because every time I talk to you, I'm like, oh, you know, this is an exciting story. You know, I need to be involved in diagnosis. Can you tell us why they should be so excited? I'm going to tell you why. Number one, this pandemic is going to slow down, you know, probably mid-year or around September. Our customer base is going to restart probably July. So we're getting set to actually increase our revenues. We have very little debt. We have $125,000 a debt. We only have 65 million shares. So we're not diluted with, like, you know, other companies that have 2-300 million shares out there. We're creating the value for the shareholders. We're creating value for the patients. And I think that the patients will actually be our best seller at the end of the day. And I promise you some things are coming and they will come. So that's why. Well, you heard it here at Investor Intel. Andre, thank you so much for joining us. And please promise me you're going to start doing these once a month with me. Absolutely. Thank you. Thank you. Bye-bye.